Melatonin treatment improves primary progressive multiple sclerosis: A case report

Journal of Pineal Research

Volumn 58, Issue 2, 2015, Pages 173-177

  Lõpez González, Antonio ^a   Álvarez Sánchez, Nuria ^a,b   Lardone, Patricia J ^a   Cruz Chamorro, Ivan ^a   Martínez Lõpez, Alicia ^a   Guerrero, Juan M ^a   Reiter, Russel J ^c   Carrillo Vico, Antonio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

melatonin; multiple sclerosis; primary progressive multiple sclerosis

Indexed keywords

MELATONIN; METHYLPREDNISOLONE;

ADULT; ARTICLE; ATAXIA; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLIMBING; CONUS MEDULLARIS; CORPUS CALLOSUM; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION IMPROVEMENT; HAND PARESTHESIA; HUMAN; MULTIPLE SCLEROSIS; MUSCLE SPASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; SPASTICITY; STEROID THERAPY; TREATMENT WITHDRAWAL; WHITE MATTER; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PATHOLOGY;

ADULT; FEMALE; HUMANS; MELATONIN; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE;

EID: 84922785909     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12203     Document Type: Article

References (47)

1. Milo R, Kahana E,. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmunity Rev 2010; 9: A387-A394.
2. Sellner J, Kraus J, Awad A, et al. The increasing incidence and prevalence of female multiple sclerosis-a critical analysis of potential environmental factors. Autoimmunity Rev 2011; 10: 495-502.
3. Gourraud PA, Harbo HF, Hauser SL, et al. The genetics of multiple sclerosis: an up-to-date review. Immunological Rev 2012; 248: 87-103.
4. Tselis A,. Evidence for viral etiology of multiple sclerosis. Semin Neurol 2011; 31: 307-316.
5. Simpson S Jr, Blizzard L, Otahal P, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82: 1132-1141.
6. Kragt J, Van Amerongen B, Killestein J, et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009; 15: 9-15.
7. Ahlgren C, Oden A, Lycke J,. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011; 17: 901-908.
8. Gaby A,. Multiple sclerosis. Glob Adv Health Med 2013; 2: 50-56.
9. Mechelli R, Annibali V, Ristori G, et al. Multiple sclerosis etiology: beyond genes and environment. Expert Rev Clin Immunol 2010; 6: 481-490.
10. Frohman EM, Racke MK, Raine CS,. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-955.
11. Zamvil SS, Steinman L,. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8: 579-621.
12. Arnold P, Mojumder D, Detoledo J, et al. Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathways. Clin Pharmacol 2014; 6: 35-42.
13. Adamczyk-Sowa M, Pierzchala K, Sowa P, et al. Melatonin acts as antioxidant and improves sleep in MS patients. Neurochem Res 2014; 39: 1585-1593.
14. Lublin FD, Reingold SC,. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
15. Miller DH, Leary SM,. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6: 903-912.
16. Koch MW, Greenfield J, Javizian O, et al. The natural history of early versus late disability accumulation in primary progressive MS. J Neurol Neurosurg Psychiatry 2014. pii: jnnp-2014-307948. doi: 10.1136/jnnp-2014-307948.
17. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
18. Koch M, Kingwell E, Rieckmann P, et al. The natural history of primary progressive multiple sclerosis. Neurology 2009; 73: 1996-2002.
19. Tremlett H, Paty D, Devonshire V,. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005; 65: 1919-1923.
20. Wolinsky JS, PROMiSe Trial Study Group. The PROMiSe trial: baseline data review and progress report. Mult Scler 2004; 10 (Suppl 1): S65-S71; discussion S71-72.
21. Tremlett H, Zhu F, Petkau J, et al. Natural, innate improvements in multiple sclerosis disability. Mult Scler 2012; 18: 1412-1421.
22. Carrillo-Vico A, Lardone PJ, Alvarez-Sanchez N, et al. Melatonin: buffering the immune system. Int J Mol Sci 2013; 14: 8638-8683.
23. Mauriz JL, Collado PS, Veneroso C, et al. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 2013; 54: 1-14.
24. Carrillo-Vico A, Guerrero JM, Lardone PJ, et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
25. Calvo JR, Gonzalez-Yanes C, Maldonado MD,. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res 2013; 55: 103-120.
26. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013; 54: 245-257.
27. Zhang HM, Zhang Y,. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res 2014; 57: 131-146.
28. Reiter RJ, Paredes SD, Manchester LC, et al. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
29. Kang JC, Ahn M, Kim YS, et al. Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci 2001; 2: 85-89.
30. Bullard DC, Hu X, Crawford D, et al. Expression of a single ICAM-1 isoform on T cells is sufficient for development of experimental autoimmune encephalomyelitis. Eur J Immunol 2014; 44: 1194-1199.
31. Karlik M, Valkovic P, Hancinova V, et al. Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis. Clin Biochem 2014; 48: 24-28.
32. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134: 1914-1924.
33. Cross AH, Manning PT, Keeling RM, et al. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998; 88: 45-56.
34. Liu JS, Zhao ML, Brosnan CF, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001; 158: 2057-2066.
35. Naidoo R, Knapp ML,. Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem 1992; 38: 2449-2454.
36. Gray E, Thomas TL, Betmouni S, et al. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol 2008; 18: 86-95.
37. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-489.
38. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9.
39. Fischer TW, Kleszczynski K, Hardkop LH, et al. Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the formation of DNA damage (8-hydroxy-2-deoxyguanosine) in ex vivo human skin. J Pineal Res 2013; 54: 303-312.
40. Martin M, Macias M, Escames G, et al. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 2000; 28: 242-248.
41. Martin-Cano FE, Camello-Almaraz C, Acuna-Castroviejo D, et al. Age-related changes in mitochondrial function of mouse colonic smooth muscle: beneficial effects of melatonin. J Pineal Res 2014; 51: 163-174.
42. Aboul-Enein F, Rauschka H, Kornek B, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003; 62: 25-33.
43. Cervantes M, Morali G, Letechipia-Vallejo G,. Melatonin and ischemia-reperfusion injury of the brain. J Pineal Res 2008; 45: 1-7.
44. Carloni S, Albertini MC, Galluzzi L, et al. Melatonin reduces endoplasmic reticulum stress and preserves sirtuin 1 expression in neuronal cells of newborn rats after hypoxia-ischemia. J Pineal Res 2014; 57: 192-199.
45. Weishaupt JH, Bartels C, Polking E, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006; 41: 313-323.
46. Reiter RJ, Tan DX, Galano A,. Melatonin: exceeding expectations. Physiology (Bethesda) 2014; 29: 325-333.
47. Sarlak G, Jenwitheesuk A, Chetsawang B, et al. Effects of melatonin on nervous system aging: neurogenesis and neurodegeneration. J Pharmacol Sci 2013; 123: 9-24.